vs
GLAUKOS Corp（GKOS）与Orchestra BioMed Holdings, Inc.（OBIO）财务数据对比。点击上方公司名可切换其他公司
GLAUKOS Corp的季度营收约是Orchestra BioMed Holdings, Inc.的4.6倍（$143.1M vs $30.9M）。Orchestra BioMed Holdings, Inc.净利率更高（20.2% vs -93.4%，领先113.6%）。Orchestra BioMed Holdings, Inc.同比增速更快（12120.2% vs 35.7%）。GLAUKOS Corp自由现金流更多（$3.9M vs $-2.3M）。过去两年Orchestra BioMed Holdings, Inc.的营收复合增速更高（606.2% vs 29.3%）
Glaukos Corp是一家专注于眼科领域的医疗科技企业，开发并商业化用于治疗青光眼、角膜疾病等眼部病症的微创手术器械、处方药物及消费级产品，主要市场覆盖北美、欧洲及亚太地区，为全球医院、眼科诊所及患者提供服务。
Orchestra BioMed Holdings是一家临床阶段医疗科技企业，专注于开发针对心血管及其他高负担慢性疾病的新型循证治疗方案，核心业务覆盖介入心脏病学、慢病护理优化等领域，主要面向北美、欧洲市场运营，与头部医疗行业参与者开展合作。
GKOS vs OBIO — 直观对比
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $143.1M | $30.9M |
| 净利润 | $-133.7M | $6.2M |
| 毛利率 | -1.1% | 99.8% |
| 营业利润率 | -97.7% | 21.8% |
| 净利率 | -93.4% | 20.2% |
| 营收同比 | 35.7% | 12120.2% |
| 净利润同比 | -298.0% | 138.7% |
| 每股收益（稀释后） | $-2.34 | $0.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $143.1M | $30.9M | ||
| Q3 25 | $133.5M | $861.0K | ||
| Q2 25 | $124.1M | $836.0K | ||
| Q1 25 | $106.7M | $868.0K | ||
| Q4 24 | $105.5M | $253.0K | ||
| Q3 24 | $96.7M | $987.0K | ||
| Q2 24 | $95.7M | $778.0K | ||
| Q1 24 | $85.6M | $620.0K |
| Q4 25 | $-133.7M | $6.2M | ||
| Q3 25 | $-16.2M | $-20.8M | ||
| Q2 25 | $-19.7M | $-19.4M | ||
| Q1 25 | $-18.1M | $-18.8M | ||
| Q4 24 | $-33.6M | $-16.2M | ||
| Q3 24 | $-21.4M | $-15.4M | ||
| Q2 24 | $-50.5M | $-16.0M | ||
| Q1 24 | $-40.8M | $-13.5M |
| Q4 25 | -1.1% | 99.8% | ||
| Q3 25 | 78.4% | 94.3% | ||
| Q2 25 | 78.3% | 94.5% | ||
| Q1 25 | 77.2% | 94.9% | ||
| Q4 24 | 72.9% | 77.1% | ||
| Q3 24 | 76.6% | 93.1% | ||
| Q2 24 | 76.4% | 94.3% | ||
| Q1 24 | 76.3% | 94.5% |
| Q4 25 | -97.7% | 21.8% | ||
| Q3 25 | -12.3% | -2359.2% | ||
| Q2 25 | -18.3% | -2311.8% | ||
| Q1 25 | -19.4% | -2179.8% | ||
| Q4 24 | -27.2% | -6591.7% | ||
| Q3 24 | -25.5% | -1655.7% | ||
| Q2 24 | -31.3% | -2167.0% | ||
| Q1 24 | -45.6% | -2326.3% |
| Q4 25 | -93.4% | 20.2% | ||
| Q3 25 | -12.2% | -2419.0% | ||
| Q2 25 | -15.8% | -2316.1% | ||
| Q1 25 | -17.0% | -2160.7% | ||
| Q4 24 | -31.8% | -6385.4% | ||
| Q3 24 | -22.1% | -1562.9% | ||
| Q2 24 | -52.8% | -2054.0% | ||
| Q1 24 | -47.7% | -2171.5% |
| Q4 25 | $-2.34 | $0.28 | ||
| Q3 25 | $-0.28 | $-0.40 | ||
| Q2 25 | $-0.34 | $-0.50 | ||
| Q1 25 | $-0.32 | $-0.49 | ||
| Q4 24 | $-0.56 | $-0.42 | ||
| Q3 24 | $-0.39 | $-0.41 | ||
| Q2 24 | $-1.00 | $-0.45 | ||
| Q1 24 | $-0.82 | $-0.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $90.8M | $106.5M |
| 总债务越低越好 | — | $15.0M |
| 股东权益账面价值 | $656.2M | $53.6M |
| 总资产 | $893.5M | $114.9M |
| 负债/权益比越低杠杆越低 | — | 0.28× |
8季度趋势，按日历期对齐
| Q4 25 | $90.8M | $106.5M | ||
| Q3 25 | $98.2M | $95.8M | ||
| Q2 25 | $100.8M | $33.9M | ||
| Q1 25 | $114.3M | $49.9M | ||
| Q4 24 | $169.6M | $66.8M | ||
| Q3 24 | $100.1M | $66.9M | ||
| Q2 24 | $68.1M | $65.2M | ||
| Q1 24 | $42.5M | $75.0M |
| Q4 25 | — | $15.0M | ||
| Q3 25 | — | $15.0M | ||
| Q2 25 | — | $15.0M | ||
| Q1 25 | — | $15.0M | ||
| Q4 24 | — | $15.0M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $656.2M | $53.6M | ||
| Q3 25 | $769.5M | $43.7M | ||
| Q2 25 | $765.1M | $295.0K | ||
| Q1 25 | $764.0M | $16.9M | ||
| Q4 24 | $766.9M | $33.0M | ||
| Q3 24 | $668.5M | $46.2M | ||
| Q2 24 | $665.2M | $44.1M | ||
| Q1 24 | $450.7M | $57.2M |
| Q4 25 | $893.5M | $114.9M | ||
| Q3 25 | $999.4M | $104.8M | ||
| Q2 25 | $987.0M | $42.8M | ||
| Q1 25 | $966.2M | $59.1M | ||
| Q4 24 | $974.8M | $76.2M | ||
| Q3 24 | $926.5M | $75.3M | ||
| Q2 24 | $919.7M | $72.4M | ||
| Q1 24 | $933.3M | $82.6M |
| Q4 25 | — | 0.28× | ||
| Q3 25 | — | 0.34× | ||
| Q2 25 | — | 50.85× | ||
| Q1 25 | — | 0.89× | ||
| Q4 24 | — | 0.46× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $6.8M | $-2.3M |
| 自由现金流经营现金流 - 资本支出 | $3.9M | $-2.3M |
| 自由现金流率自由现金流/营收 | 2.7% | -7.4% |
| 资本支出强度资本支出/营收 | 2.0% | 0.1% |
| 现金转化率经营现金流/净利润 | — | -0.36× |
| 过去12个月自由现金流最近4个季度 | $-22.5M | $-49.5M |
8季度趋势，按日历期对齐
| Q4 25 | $6.8M | $-2.3M | ||
| Q3 25 | $-10.1M | $-14.6M | ||
| Q2 25 | $7.0M | $-15.5M | ||
| Q1 25 | $-18.5M | $-16.6M | ||
| Q4 24 | $507.0K | $-13.5M | ||
| Q3 24 | $-9.6M | $-13.7M | ||
| Q2 24 | $-18.4M | $-10.2M | ||
| Q1 24 | $-33.9M | $-13.1M |
| Q4 25 | $3.9M | $-2.3M | ||
| Q3 25 | $-11.7M | $-14.9M | ||
| Q2 25 | $5.8M | $-15.6M | ||
| Q1 25 | $-20.5M | $-16.7M | ||
| Q4 24 | $-1.2M | $-13.6M | ||
| Q3 24 | $-11.0M | $-13.8M | ||
| Q2 24 | $-20.5M | $-10.3M | ||
| Q1 24 | $-34.8M | $-13.1M |
| Q4 25 | 2.7% | -7.4% | ||
| Q3 25 | -8.8% | -1725.9% | ||
| Q2 25 | 4.7% | -1861.4% | ||
| Q1 25 | -19.2% | -1927.2% | ||
| Q4 24 | -1.2% | -5392.9% | ||
| Q3 24 | -11.4% | -1394.9% | ||
| Q2 24 | -21.4% | -1325.6% | ||
| Q1 24 | -40.7% | -2116.5% |
| Q4 25 | 2.0% | 0.1% | ||
| Q3 25 | 1.2% | 36.0% | ||
| Q2 25 | 0.9% | 4.1% | ||
| Q1 25 | 1.8% | 12.9% | ||
| Q4 24 | 1.6% | 41.9% | ||
| Q3 24 | 1.5% | 6.9% | ||
| Q2 24 | 2.2% | 13.8% | ||
| Q1 24 | 1.1% | 1.3% |
| Q4 25 | — | -0.36× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GKOS
| Glaucoma | $86.4M | 60% |
| Other | $35.1M | 25% |
| Corneal Health | $21.6M | 15% |
OBIO
暂无分部数据
